Polyamines in Down syndrome-Alzheimer's disease

Paredes, Daniel A

Early onset Alzheimer's disease occurs in eighty percent of individuals with Down syndrome with few therapeutic options available. This study provides the opportunity to use the polyamine pathway as a potential drug target that could be a contributing factor in the development of neuropathology underlying dementia in Down syndrome.

Down Syndrome Publications